A61K9/5052

COMPOSITION CONTAINING MICROCAPSULE AND CELL STRUCTURE

An object of the present invention is to provide a composition containing at least microcapsules and cell structures, where the composition can exhibit a high treatment effect in a case of being transplanted into a living body. There is provided a composition including at least (a) a microcapsule containing a polymer hydrogel; and (b) a cell structure containing a biocompatible polymer block and a cell, in which a plurality of biocompatible polymer blocks are arranged in gaps between a plurality of cells, where at least a part of the cell structures are encapsulated in the microcapsules.

Microencapsulation of bacteriophages and related products

An encapsulated bacteriophage formulation and a method for encapsulating bacteriophages and bacteriophage-related products in polymeric microcapsules is provided. Some embodiments of the method of producing the encapsulated bacteriophages involves a water-in-oil-in-water double emulsion.

Mineralizing biosurfactant used for nucleating silica

The present invention relates to emulsion-templated silica micro and nano-capsules- and methods for making them. In particular, the template emulsion is stabilized by a biosurfactant that also assists in nucleating the silica shell Mineralizing biosurfactants and stabilized micro- and nano-emulsions useful in forming the emulsion-templated micro- and nano-capsules, and methods for the use of the silica micro- and nano-capsules are also described.

Biodegradable extended release microsphere-hydrogel ocular drug delivery system and method

A hydrogel delivery composition and method, including degradable microcapsules suspended in a degradable thermo-responsive hydrogel. The hydrogel is thermo-responsive at a physiological temperature and changes after application to a more solid state due to body temperatures. The composition includes one or more treatment agents to be released over time as the composition degrades. The composition can be varied to modify the structure and/or release of the treatment agent. The degradable microcapsules include one or more of magnesium hydroxide (Mg(OH).sub.2), bovine serum albumin (BSA), polyethylene glycol (PEG), and sucrose to improve release duration.

METHOD OF DRUG FORMULATION BASED ON INCREASING THE AFFINITY OF ACTIVE AGENTS FOR CRYSTALLINE MICROPARTICLE SURFACES
20230390206 · 2023-12-07 · ·

Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle.

Active component encapsulated, protected and stabilized within a protein shell
11135175 · 2021-10-05 · ·

A microcapsule includes an active component encapsulated within a polymerized hydrolyzed protein shell. The microcapsule has an average diameter that is less than one hundred micrometers as determined by a laser diffractometer.

Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
11103459 · 2021-08-31 · ·

Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle.

Gastro-resistant microencapsulates, and uses thereof to stimulate in-vivo ileal GLP-1 release in a mammal
11103550 · 2021-08-31 · ·

A cold-gelated mono-nuclear microencapsulate comprises a unitary liquid core encapsulated within a gastro-resistant, ileal-sensitive, polymerized denatured protein membrane shell, wherein the liquid core comprises a GLP-1 release stimulating agent in a substantially solubilised form. The GLP-1 release stimulating agent is a native protein selected from native dairy protein, native vegetable protein or native egg protein.

METHODS, COMPOSITIONS, AND DEVICES FOR DRUG / LIVE CELL MICROARRAYS
20210275472 · 2021-09-09 ·

This invention discloses methods and composition to form biodegradable polymer implant arrays in the live tissue. Artificial cavities are created in the live tissue by using laser ablation, oscillating needle, microneedle array and other methods. The cavities are then filled with biodegradable polymer solution. The solvent in the polymer solution is dissipated in the tissue to form a biodegradable polymer implant in artificial cavities. The cavities and implants formed are arranged to form of an array of implants. The biodegradable polymer in the cavity can also be loaded with drug to form biodegradable drug delivery array in the live tissue.

METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF FRIEDREICH'S ATAXIA
20210220431 · 2021-07-22 ·

The disclosure provides methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia, and/or reducing the likelihood or severity of Friedreich's ataxia. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to e.g., reduce oxidative stress, increase mitochondrial metabolism, or a combination thereof.